Biogen Pharmachem Industries Ltd
₹0.54
(0%)
Sun, 22 Mar 2026, 06:01 am
Finance
Investment Banks/Brokers
24.5KBiogen Pharmachem Industries Ratios
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 84.29 | 35.81 | 0 |
| Price to book ratio | 0 | 0 | 0.32 | 0.09 | 0.42 | 0.26 | 0.22 | 0.32 | 0.22 | 0.24 | 0.23 | 0.23 | 0.28 | 0.22 | 0.25 | 1.69 | 0.71 | 1.22 | 0.68 |
| Price to sales ratio | 0 | 0 | 0.01 | 1.80 | 62.99 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 15.80 | 0 | 947.16 | 42.13 | 42.18 | 29.05 | 74.73 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0.10 | 55.06 | 0 | 0.48 | 0 | 0 | 171.52 | 0 | 3.47 | 65.34 | 22.59 | 35.57 | 0 |
| Enterprise value | 0 | 0 | 21.08M | 33.47M | -119.13M | 15.92M | -418.55M | 136.33M | -125.31M | -57.33M | -23.76M | 123.9M | 156.37M | 127.02M | 136.97M | 912.81M | 383.75M | 691.59M | 606.34M |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | -449.99 | 646.61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 84.23 | 35.82 | 0 |
| Debt to equity ratio | 0 | 0 | 0 | 0 | 0 | 0.07 | 0.04 | 0.94 | 0.16 | 0.10 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 |
| Return on equity % | 0 | -2.20 | -49.20 | -0.03 | -0.31 | -0.15 | -0.22 | -0.21 | -0.22 | -0.05 | -0.20 | -11.40 | -0.01 | -0.21 | -2.92 | -0.02 | 0.84 | 3.48 | -0.39 |
Biogen Pharmachem Industries Ltd Ratios
The Biogen Pharmachem Industries Ltd Ratios page provides a complete fundamental analysis of Biogen Pharmachem Industries Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Biogen Pharmachem Industries Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Biogen Pharmachem Industries Ltd (NSE: , BSE: 531752) is currently trading at ₹0.54, with a market capitalization of ₹487.41M. As a major player in the Finance sector and Investment banks/Brokers industry, Biogen Pharmachem Industries Ltd remains a key stock for fundamental analysis using Biogen Pharmachem Industries Ltd Ratios.
Biogen Pharmachem Industries Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Biogen Pharmachem Industries Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Biogen Pharmachem Industries Ltd Ratios.
Historically, the Biogen Pharmachem Industries Ltd P/E ratio has shown strong fluctuations:
- 2024: 0
- 2023: 35.81
- 2022: 84.29
- 2021: 0
- 2020: 0
The decline in Biogen Pharmachem Industries Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Biogen Pharmachem Industries Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.68.
Historical P/B trend:
- 2024: 0.68
- 2023: 1.22
- 2022: 0.71
- 2021: 1.69
Biogen Pharmachem Industries Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Biogen Pharmachem Industries Ltd P/S ratio currently stands at 74.73, an important part of Biogen Pharmachem Industries Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 74.73
- 2023: 29.05
- 2022: 42.18
- 2021: 42.13
The rising Biogen Pharmachem Industries Ltd P/S ratio indicates improved revenue valuation by investors.
Biogen Pharmachem Industries Ltd Price to Cash Flow Ratio (P/CF)
The Biogen Pharmachem Industries Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.
Historical Biogen Pharmachem Industries Ltd Price to Cash Flow Ratio:
- 2024: 0
- 2023: 35.57
- 2022: 22.59
- 2021: 65.34
- 2020: 3.47
The declining Biogen Pharmachem Industries Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Biogen Pharmachem Industries Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Biogen Pharmachem Industries Ltd EV currently stands at ₹606.34M, representing the total company valuation including debt.
Historical EV trend:
- 2024: 606.34M
- 2023: 691.59M
- 2022: 383.75M
- 2021: 912.81M
Biogen Pharmachem Industries Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Biogen Pharmachem Industries Ltd EV/EBITDA ratio is currently 0, a key metric in Biogen Pharmachem Industries Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 0
- 2023: 35.82
- 2022: 84.23
- 2021: 0
Stable Biogen Pharmachem Industries Ltd EV/EBITDA indicates balanced valuation.
Biogen Pharmachem Industries Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Biogen Pharmachem Industries Ltd D/E ratio is currently 0, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0
Biogen Pharmachem Industries Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Biogen Pharmachem Industries Ltd ROE currently stands at -0.39%, showing profitability and capital efficiency.
Historical ROE:
- 2024: -0.39
- 2023: 3.48
- 2022: 0.84
- 2021: -0.02
Declining ROE indicates pressure on profitability.
Biogen Pharmachem Industries Ltd Ratios Analysis Summary
The Biogen Pharmachem Industries Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Biogen Pharmachem Industries Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Biogen Pharmachem Industries Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800